The Remarkable Journey of Fondaparinux – Abdul Mannan
Dr. Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
“The Remarkable Journey of Fondaparinux:
The story begins with Jay McLean’s accidental discovery of heparin at Johns Hopkins in 1916. Decades later, Harvard and Uppsala scientists revealed heparin’s mechanism – supercharging antithrombin by 1000-fold.
The Breakthrough (1980s):
Researchers discovered a pentasaccharide sequence within heparin was responsible for anticoagulation – The exact key that unlocks antithrombin’s potential.The Innovation (1987):
Maurice Petitou’s team at Institut Choay achieved the impossible – synthesizing the first artificial pentasaccharide (SR90107A/Org31540): The fondaparinux.Clinical Success (2002):
Trials involving 7,000+ patients, fondaparinux (Arixtra) showed 55% RR reduction in VTE. Sanofi brought this revolutionary anticoagulant to market.Why It Matters:
– Selective Xa inhibition
– No HIT risk
– Fixed dosing , no monitoring
– Synthetic precision over natural variabilityThis journey shows how molecular insight transforms patient care. Fondaparinux remains key in VTE prevention and led to modern anticoagulants.
What breakthrough in hemostasis research inspires you most?”
Don’t miss the latest updates with Hemostasis Today.
-
Aug 26, 2025, 10:02Women’s Equality Day: HFA Recognizes Women with Bleeding Disorders
-
Aug 26, 2025, 09:59Rare Disease Advisor – RBC Rheology Alterations in Hemophilia with Arthropathy
-
Aug 26, 2025, 09:57HFA Supports Future Planning for People with Bleeding Disorders
-
Aug 26, 2025, 09:56Phillip Taboada: TXA Shows No Added Benefit in Aquablation
-
Aug 26, 2025, 09:50A Global Collaboration: PERT Consortium Expands Reach in PE Care
-
Aug 26, 2025, 09:54TSUBASA Study: Emicizumab Improves Daily Life and Motivation in Hemophilia A Patients
-
Aug 26, 2025, 09:38Advancing CAT Care: New Insights on Extended Anticoagulation from Gerotziafas and Tafur
-
Aug 26, 2025, 09:35Alexander Mazein: Innovative Insights into Cytokine Release Syndrome via a Novel Explorable Model for Biotherapeutics and Cellular Therapies
-
Aug 25, 2025, 10:40Maria Filomena Ruberto on The Hypercoagulable State
-
Aug 25, 2025, 09:19Parham Dastjerdi – Clonal Hematopoiesis and VTE Risk
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 26, 2025, 09:42David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
-
Aug 23, 2025, 07:48Protecting Heart and Brain Health: Stroke Prevention in Women with Bleeding Disorders: NBDF
-
Aug 21, 2025, 15:08Global Variations in Blood Collection: What Explains the Differences?
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!